Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 880881107 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Morgan Stanley 13G/A Amendment 2 | 0% |
6/5/2026
Event 5/31/2026
|
|
|
Adage Capital Management, L.P.
13G/A
Amendment 1
|
1.8% |
5/13/2026
Event 3/31/2026
|
|
| Adage Capital Management, L.P. | 1.8% | ||
| Robert Atchinson | 1.8% | ||
| Phillip Gross | 1.8% | ||
|
Morgan Stanley
13G/A
Amendment 1
|
5.6%
Checked 5% or less
|
5/12/2026
Event 3/31/2026
|
|
| Morgan Stanley | 5.6% | ||
| Morgan Stanley Capital Services LLC | 4.9% | ||
| Vanguard Group Inc 13G/A Amendment 1 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
Commodore Capital LP
13G/A
Amendment 2
|
1.4% |
2/17/2026
Event 12/31/2025
|
|
| Commodore Capital LP | 1.4% | ||
| Commodore Capital Master LP | 1.4% | ||
| Robert Egen Atkinson | 1.4% | ||
| Michael Kramarz | 1.4% | ||
|
Vivo Opportunity Fund Holdings, L.P.
13G/A
Amendment 3
|
2.5% |
2/13/2026
Event 1/31/2025
|
|
| Vivo Capital Fund VIII, L.P. | 0.9% | ||
| Vivo Capital Surplus Fund VIII, L.P. | 0.1% | ||
| Vivo Capital VIII, LLC | 1.0% | ||
| Vivo Opportunity Fund Holdings, L.P. | 2.5% | ||
| Vivo Opportunity, LLC | 2.5% | ||
| Vivo Opportunity Cayman Fund, L.P. | 0.2% | ||
| Vivo Opportunity Cayman, LLC | 0.2% | ||
|
Deep Track Capital, LP
13G/A
Amendment 4
|
3.0% |
2/13/2026
Event 12/31/2025
|
|
| Deep Track Capital, LP | 3.0% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 3.0% | ||
| David Kroin | 3.0% | ||
|
Soleus Capital Master Fund, L.P.
13G/A
Amendment 3
|
0.2% |
2/12/2026
Event 12/31/2025
|
|
| Soleus Capital Master Fund, L.P. | 0.2% | ||
| Soleus Capital, LLC | 0.2% | ||
| Soleus Capital Group, LLC | 0.2% | ||
| Soleus Capital Management, L.P. | 0.2% | ||
| Soleus GP, LLC | 0.2% | ||
| Guy Levy | 0.2% | ||
|
Adage Capital Management, L.P.
13G
|
5.1% |
2/12/2026
Event 12/31/2025
|
|
| Adage Capital Management, L.P. | 5.1% | ||
| Robert Atchinson | 5.1% | ||
| Phillip Gross | 5.1% | ||
|
Commodore Capital LP
13G/A
Amendment 1
|
6.5% |
11/14/2025
Event 9/30/2025
|
|
| Commodore Capital LP | 6.5% | ||
| Commodore Capital Master LP | 6.5% | ||
| Robert Egen Atkinson | 6.5% | ||
| Michael Kramarz | 6.5% | ||
|
Orbimed Advisors LLC
13D/A
Amendment 6
|
4.8% |
11/5/2025
Event 11/3/2025
|
|
| Orbimed Advisors LLC | 4.8% | ||
| Orbimed Capital GP VII LLC | 3.1% | ||
| OrbiMed Asia GP III, L.P. | 1.2% | ||
| OrbiMed Advisors III Ltd | 1.2% | ||
| OrbiMed Genesis GP LLC | 0.5% | ||
| Vanguard Group Inc 13G | 5.2% |
10/31/2025
Event 9/30/2025
|
|
|
Commodore Capital LP
13G
|
5.3% |
9/16/2025
Event 9/9/2025
|
|
| Commodore Capital LP | 5.3% | ||
| Commodore Capital Master LP | 5.3% | ||
| Robert Egen Atkinson | 5.3% | ||
| Michael Kramarz | 5.3% | ||
|
Deep Track Capital, LP
13G/A
Amendment 3
|
8.6% |
8/14/2025
Event 6/30/2025
|
|
| Deep Track Capital, LP | 8.6% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 8.6% | ||
| David Kroin | 8.6% | ||
| Schonfeld Strategic Advisors LLC 13G/A Amendment 2 | 4.9% |
5/15/2025
Event 3/31/2025
|
|
|
Deep Track Capital, LP
13G/A
Amendment 2
|
6.4% |
5/15/2025
Event 3/31/2025
|
|
| Deep Track Capital, LP | 6.4% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 6.4% | ||
| David Kroin | 6.4% | ||
|
Morgan Stanley
13G
|
8.1% |
5/7/2025
Event 3/31/2025
|
|
| Morgan Stanley | 8.1% | ||
| Morgan Stanley Capital Services LLC | 7.0% | ||
| Schonfeld Strategic Advisors LLC 13G/A Amendment 1 | 6.2% |
2/14/2025
Event 12/31/2024
|
|
|
Citadel Advisors LLC
13G/A
Amendment 1
|
4.1% |
2/14/2025
Event 12/31/2024
|
|
| Citadel Advisors LLC | 3.9% | ||
| Citadel Advisors Holdings LP | 3.9% | ||
| Citadel GP LLC | 3.9% | ||
| Citadel Securities LLC | 0.2% | ||
| Citadel Securities Group LP | 0.2% | ||
| Citadel Securities GP LLC | 0.2% | ||
| Kenneth Griffin | 4.1% | ||
|
Soleus Capital Master Fund, L.P.
13G/A
Amendment 2
|
9.6% |
2/11/2025
Event 12/31/2024
|
|
| Soleus Capital Master Fund, L.P. | 9.6% | ||
| Soleus Capital, LLC | 9.6% | ||
| Soleus Capital Group, LLC | 9.6% | ||
| Soleus Capital Management, L.P. | 9.6% | ||
| Soleus GP LLC | 9.6% | ||
| Guy Levy | 9.6% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 6.8% |
2/5/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 2 | 12.5 k | $660 k |
| 2026 Q1 | 361 | 125 M | $6.56 B |
| 2025 Q4 | 259 | 123 M | $4.95 B |
| 2025 Q3 | 151 | 89.3 M | $671 M |
| 2025 Q2 | 136 | 83.3 M | $311 M |
| 2025 Q1 | 146 | 83.1 M | $230 M |
| 2024 Q4 | 165 | 88.1 M | $488 M |
| 2024 Q3 | 170 | 79.6 M | $663 M |
| 2024 Q2 | 136 | 66.1 M | $450 M |
| 2024 Q1 | 122 | 64.8 M | $425 M |
| 2023 Q4 | 114 | 65.6 M | $426 M |
| 2023 Q3 | 101 | 61.7 M | $310 M |
| 2023 Q2 | 113 | 57.7 M | $505 M |
| 2023 Q1 | 80 | 53.2 M | $630 M |
| 2022 Q4 | 67 | 49.8 M | $507 M |
| 2022 Q3 | 46 | 30.3 M | $178 M |
| 2022 Q2 | 43 | 14.7 M | $36.6 M |
| 2022 Q1 | 45 | 16.8 M | $50.0 M |
| 2021 Q4 | 38 | 16.5 M | $117 M |
| 2021 Q3 | 35 | 16.7 M | $174 M |
| 2021 Q2 | 37 | 16.6 M | $204 M |
| 2021 Q1 | 43 | 17.9 M | $394 M |